Before you read. This guide is educational and does not replace your Medication Guide, pharmacist, prescriber, diagnosis, or emergency care. It cannot tell you what is causing a symptom you are having — only a clinician who knows your history can do that. Nothing here tells you to start, stop, or change a dose. A symptom that is severe, persistent, or frightening is a reason to contact your care team now, not to keep reading.
Quick answer
"Does Rybelsus cause X?" has three possible answers on a drug label, and almost every page that answers this question collapses them into one.
- The symptom is in the adverse-reactions table, with a percentage. It was counted in controlled trials and compared against placebo. Nausea, diarrhea, constipation and abdominal pain live here.
- The symptom is listed in postmarketing experience, with no percentage. People reported it after approval. Headache and dizziness live here — and the label itself says these reports come from a population of uncertain size, so a frequency cannot be reliably estimated and causation cannot be established.
- The symptom is not on the label at all. Fatigue, insomnia and leg cramps are in this group. That does not mean nobody experiences them. It means the label does not claim them.
Most of the internet answers every one of these with a confident "yes." This page goes symptom by symptom and says which of the three applies.
What this page is not
This is the symptom-by-symptom view. If you want the whole picture in one place — the frequency table read in order, the boxed warning, the nine warnings and precautions, how long reactions tend to last and what counts as long-term — that is the full side-effect picture, dose by dose, and it is the better starting point if you are new to the drug.
Come here when you have one specific question about one specific symptom.
The gut symptoms that carry a number
These come from Table 2 of the label, drawn from two placebo-controlled trials in adults with type 2 diabetes: 1,071 patients exposed to semaglutide tablets, mean exposure 41.8 weeks. The table reports reactions occurring in at least 5% of treated patients and more often than on placebo.
| Adverse reaction | Placebo (N=362) | 7 mg (N=356) | 14 mg (N=356) |
|---|---|---|---|
| Nausea | 6% | 11% | 20% |
| Abdominal pain | 4% | 10% | 11% |
| Diarrhea | 4% | 9% | 10% |
| Decreased appetite | 1% | 6% | 9% |
| Vomiting | 3% | 6% | 8% |
| Constipation | 2% | 6% | 5% |
So: yes to nausea, yes to stomach pain, yes to diarrhea, yes to constipation, yes to vomiting — all with a number attached, and all more common than placebo.
Read the placebo column before you read anything else. Six percent of people who took no drug at all reported nausea. The honest reading of any row is not "how likely this is" but "how much more likely than nothing," and for nausea at 14 mg that gap is 20% against 6%.
Notice too that constipation does not rise with dose the way nausea does: 6% at 7 mg, 5% at 14 mg. Not every symptom on this drug is dose-related in the same way, which is why a single sentence about "GI side effects" hides more than it explains.
Taken as a group, gastrointestinal reactions occurred in 41% of patients on 14 mg, 32% on 7 mg, and 21% on placebo. Severe gastrointestinal reactions were reported in 2.0%, 0.6% and 0.3% respectively.
For what any of this implies about eating, what the label restricts about food, and what it leaves to you separates the actual rules from the advice.
Gas, bloating, burping, indigestion, heartburn
All four are on the label, all four sit below the 5% line, and their numbers are small enough that the placebo column matters more than usual. The label gives these as 14 mg, 7 mg and placebo respectively:
| Reaction | 14 mg | 7 mg | Placebo |
|---|---|---|---|
| Abdominal distension (bloating) | 3% | 2% | 1% |
| Dyspepsia (indigestion) | 0.6% | 3% | 0.6% |
| Eructation (burping) | 2% | 0.6% | 0% |
| Flatulence (gas) | 1% | 2% | 0% |
| Gastroesophageal reflux disease (heartburn) | 2% | 2% | 0.3% |
| Gastritis | 2% | 2% | 0.8% |
So the answer to "does Rybelsus cause gas / bloating / burping / indigestion / heartburn" is yes, all are listed — but at low single-digit rates, and two of them (dyspepsia, flatulence) were actually reported more often at 7 mg than at 14 mg. With numbers this small, that inversion is noise rather than a finding, and it is a useful reminder not to read a 1% difference as a trend.
Headaches and dizziness: listed, but not counted
This is the pair that most needs the distinction made at the top of this page.
Headache and dizziness are not in the adverse-reactions table. They appear in section 6.2, Postmarketing Experience, under nervous system disorders, alongside dysesthesia and dysgeusia — an altered sense of touch and an altered sense of taste.
The label introduces that entire section with a caveat worth quoting in full, because it is the part that never survives being summarized:
The following adverse reactions have been reported during post-approval use of semaglutide, the active ingredient in RYBELSUS and OZEMPIC tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Read that twice. "Reported" is not "caused." A postmarketing listing means people taking the drug reported the symptom often enough for it to be recorded — not that a trial measured it, not that it beat placebo, and not that the drug was shown to be the reason.
So: does Rybelsus cause headaches? The label lists headache, without a frequency, in postmarketing reports. Same answer for dizziness. That is a different kind of answer from the nausea one, and anyone telling you "headache affects X% of people on Rybelsus" is quoting a number the label does not contain.
Fatigue, insomnia, leg cramps: not on the label
Three of the most-searched symptoms on this drug are not in the US prescribing information at all. Not in the adverse-reactions table, not below the 5% line, not in postmarketing experience.
- Fatigue — not listed
- Insomnia — not listed
- Muscle or leg cramps — not listed
This is the most useful thing on this page, and it is the answer you will almost never find, because "no" makes a bad article and a worse headline.
What it does and does not mean. It does not mean these symptoms are imaginary, and it does not mean they are unrelated to anything you are experiencing. Eating substantially less — and decreased appetite is on the label, at 9% on 14 mg against 1% on placebo — can produce tiredness on its own. Dehydration from vomiting or diarrhea can produce lightheadedness and cramping on its own. Neither of those routes requires the drug to have a direct effect the label would list.
What it does mean is that if you read "Rybelsus causes fatigue" somewhere, that claim is not coming from the label. Bring the symptom to your prescriber as a symptom, with dates, rather than as a diagnosis you arrived at from a search result.
A symptom with a date attached is a different conversation from a symptom without one. Takely records what you took, when, and a one-line note on how the day went, all on one private timeline — so "since the increase, roughly a week" is available instead of "for a while now." Open Takely in your browser →
Does Rybelsus cause kidney problems?
Acute kidney injury is on the label twice: in postmarketing experience under renal, and as its own warning in section 5.5. The warning is specific about the mechanism, and the mechanism is the point:
There have been postmarketing reports of acute kidney injury in some cases requiring hemodialysis, in patients treated with semaglutide. The majority of the reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea. Monitor renal function in patients reporting adverse reactions to RYBELSUS or OZEMPIC tablets that could lead to volume depletion, especially during dosage initiation and escalation.
The label's own framing is that most reported events followed dehydration from gastrointestinal reactions, not a direct effect on the kidney. The heading itself says so: acute kidney injury due to volume depletion.
Which turns an abstract worry into something concrete. Sustained vomiting or diarrhea, particularly during a dose increase, is the situation the label is describing — and it is a reason to contact your care team rather than to wait it out.
Does Rybelsus cause gastroparesis?
The label does not list gastroparesis as an adverse reaction. It addresses it from the other direction, as a pre-existing condition:
RYBELSUS and OZEMPIC tablets are not recommended in patients with severe gastroparesis.
Separately, the label states that these tablets delay gastric emptying, and that this delay has the potential to affect the absorption of other oral drugs. Delayed gastric emptying is a known pharmacological effect of the drug class; it is also the mechanism behind the pulmonary-aspiration warning for people undergoing general anesthesia or deep sedation.
So the accurate answer is layered. Slowed stomach emptying: yes, that is how the drug works. Gastroparesis as a diagnosed condition caused by the drug: not something the label claims. Severe gastroparesis already present: a reason the label says not to use it.
If you have a gastroparesis diagnosis, or are being worked up for one, that belongs in the conversation with whoever prescribes this.
Does Rybelsus cause weight loss?
In the US, weight loss is not an approved use of Rybelsus. Its label, now shared with Ozempic tablets, carries two indications: improving glycemic control in adults with type 2 diabetes, and reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for those events.
What the label does contain is decreased appetite as an adverse reaction — 9% at 14 mg, 6% at 7 mg, 1% on placebo — and body-weight change reported as a secondary measure in its clinical studies section.
We do not reprint those weight figures here. They are trial averages under trial conditions, they say nothing about any individual, and quoting them on a page about symptoms would turn an adverse-reaction listing into a performance claim. They are in the label's clinical studies section, linked below, and they belong read in that context.
If weight is the reason you are asking, the drugs approved for it are a different conversation — Rybelsus vs Wegovy covers the one-molecule, two-prescriptions version of that question.
Does Rybelsus cause hair loss?
Alopecia is listed in postmarketing experience, under skin and subcutaneous tissue. Same caveat as headache and dizziness: reported after approval, no frequency, no established causation.
Worth knowing alongside that: hair shedding is a recognised response to rapid weight change and to reduced intake generally, through a mechanism that has nothing to do with any specific drug. The label lists the report; it does not explain it.
Why escalation weeks are when most of this happens
One pattern runs through nearly every answer above, and it is the practical takeaway.
The label ties its gastrointestinal reactions to dose escalation, sets the 3 mg starting dose aside as an initiation dose that is not effective for glycemic control, and instructs a 30-day hold before each increase specifically to reduce the risk of those reactions. The kidney warning names dosage initiation and escalation as the period to watch. The whole shape of the ladder exists because of when symptoms cluster.
Which means the single most useful thing you can bring to an appointment is not a symptom list. It is a symptom list with dates, lined up against the dates your dose changed.
"Nausea for about five days after each increase, then it settled" is a sentence a prescriber can act on. "I have been feeling sick" is not, and it is what most of us actually produce three months later. Takely exists to record a symptom with the date it started next to the dose that was running at the time. For the mechanics of the morning itself, the 30-minute wait, step by step covers where the routine usually breaks.
Frequently asked questions
Does Rybelsus cause nausea?
Yes, and it is the most common adverse reaction in the label's table: 20% at 14 mg and 11% at 7 mg, against 6% on placebo. Gastrointestinal reactions as a group occurred in 41% of patients on 14 mg versus 21% on placebo, and the label ties them to dose escalation.
Does Rybelsus cause headaches?
Headache is listed in the label's postmarketing experience section under nervous system disorders, with no frequency given. The label states those reports come from a population of uncertain size, so their frequency cannot be reliably estimated and causation cannot be established. It is not in the adverse-reactions table.
Does Rybelsus cause fatigue or insomnia?
Neither appears anywhere in the US prescribing information — not in the adverse-reactions table and not in postmarketing experience. That is not the same as saying nobody experiences them. Decreased appetite is listed at 9% on 14 mg, and eating substantially less can produce tiredness without any direct drug effect.
Does Rybelsus cause kidney problems?
Acute kidney injury appears in postmarketing reports and has its own warning, titled acute kidney injury due to volume depletion. The label says the majority of reported events occurred in people who had gastrointestinal reactions leading to dehydration, and advises monitoring renal function during dose initiation and escalation.
Does Rybelsus cause leg cramps?
Muscle cramps and leg cramps do not appear in the label. Dehydration from vomiting or diarrhea can cause cramping on its own, and those reactions are listed, so the symptom can be real without the drug having a direct effect the label records. Bring it to your prescriber with dates.
Primary sources and further reading
- FDA Prescribing Information — RYBELSUS (semaglutide) tablets and OZEMPIC (semaglutide) tablets, sections 5.5, 5.6, 5.9, 6.1, 6.2 and 14; indications revised 10/2025, dosage revised 12/2025 ↗
- FDA label via DailyMed — RYBELSUS / OZEMPIC (semaglutide) tablets ↗
- EMA — Rybelsus, product information (Annex I, section 4.8 Undesirable effects) ↗
- Buckley ST, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med 2018;10(467):eaar7047. PMID 30429357 ↗
Labels are revised. Everything on this page was checked against the sources above on 30 August 2026. Check the current label and ask your clinician or pharmacist about your own prescription.